From Yahoo finance discussionsIn my opinion the best case scenario would be a successful harvest in the forecast timeline and a b2b sale with a a good margin. Then after the news and a share price of approx 0.06 CAD $ the company is bought by a bigger company for a premium price of 0.15 - 0.20 CAD $. Worst case scenario would be another fail of generating revenue this summer leaving us with more dilution in the end or even forced to sell more assets/shares of Organigram to fund the ongoing business(es). I am not even writing what our share price would be then.
Trying to survive on their own would mean another (approx. 2 years) waiting time, given that they are also way behind in retrofitting the rest of the greenhouse. Growing with 1/4 of the space and only Farmako as a small revenue generator maybe enough to survive - but would leave no room for substantial growth and ultimately the share price will hover around 0.05 to maybe 0.10 CAD $ for at least 2023...
I think its dead money here for all long term investors since 2019. All new investors may have a great chance of getting 300-500% in the next months without the risk to lose much of their initial investment. I mean well, we have bottom bottomed somehow...